{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:21:43Z","timestamp":1774308103872,"version":"3.50.1"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013374","name":"NIHR School for Primary Care Research","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100013374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Schizophrenia and bipolar disorder are severe mental illnesses which are highly prevalent worldwide. Risperidone and Paliperidone are treatments for either illnesses, but their efficacy compared to other antipsychotics and growing reports of hormonal imbalances continue to raise concerns\n                      <jats:italic>.<\/jats:italic>\n                      As existing evidence on both antipsychotics are solely based on aggregate data, we aimed to assess the benefits and harms of Risperidone and Paliperidone in the treatment of patients with schizophrenia or bipolar disorder, using individual participant data (IPD), clinical study reports (CSRs) and publicly available sources (journal publications and trial registries).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched MEDLINE, Central, EMBASE and PsycINFO until December 2020 for randomised placebo-controlled trials of Risperidone, Paliperidone or Paliperidone palmitate in patients with schizophrenia or bipolar disorder. We obtained IPD and CSRs from the Yale University Open Data Access project. The primary outcome Positive and Negative Syndrome Scale (PANSS) score was analysed using one-stage IPD meta-analysis. Random-effect meta-analysis of harm outcomes involved methods for coping with rare events. Effect-sizes were compared across all available data sources using the ratio of means or relative risk. We registered our review on PROSPERO, CRD42019140556.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 35 studies, IPD meta-analysis involving 22 (63%) studies showed a significant clinical reduction in the PANSS in patients receiving Risperidone (mean difference \u2212 5.83, 95% CI \u2212 10.79 to \u2212 0.87,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 8.5%,\n                      <jats:italic>n<\/jats:italic>\n                      = 4 studies, 1131 participants), Paliperidone (\u2212 6.01, 95% CI \u2212 8.7 to \u2212 3.32,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 4.3%,\n                      <jats:italic>n<\/jats:italic>\n                      = 13, 3821) and Paliperidone palmitate (\u2212 7.89, 95% CI \u2212 12.1 to \u2212 3.69,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 2.9%,\n                      <jats:italic>n<\/jats:italic>\n                      = 5, 2209). CSRs reported nearly two times more adverse events (4434 vs. 2296 publication, relative difference (RD) = 1.93, 95% CI 1.86 to 2.00) and almost 8 times more serious adverse events (650 vs. 82; RD = 7.93, 95% CI 6.32 to 9.95) than the journal publications. Meta-analyses of individual harms from CSRs revealed a significant increased risk among several outcomes including extrapyramidal disorder, tardive dyskinesia and increased weight. But the ratio of relative risk between the different data sources was not significant. Three treatment-related gynecomastia events occurred, and these were considered mild to moderate in severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IPD meta-analysis conclude that Risperidone and Paliperidone antipsychotics had a small beneficial effect on reducing PANSS score over 9 weeks, which is more conservative than estimates from reviews based on journal publications. CSRs also contained significantly more data on harms that were unavailable in journal publications or trial registries. Sharing of IPD and CSRs are necessary when performing meta-analysis on the efficacy and safety of antipsychotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-021-02062-w","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T21:02:32Z","timestamp":1629838952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-0977","authenticated-orcid":false,"given":"Alexander","family":"Hodkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal R.","family":"Mahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Kontopantelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Panagioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"issue":"9659","key":"2062_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(09)60072-6","volume":"373","author":"P Lichtenstein","year":"2009","unstructured":"Lichtenstein P, Yip BH, Bj\u00f6rk C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373(9659):234\u20139 https:\/\/doi.org\/10.1016\/S0140-6736(09)60072-6.","journal-title":"Lancet"},{"key":"2062_CR2","doi-asserted-by":"publisher","unstructured":"Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;(1):Cd006626 https:\/\/doi.org\/10.1002\/14651858.CD006626.pub2 [published Online First: 2011\/01\/21].","DOI":"10.1002\/14651858.CD006626.pub2"},{"issue":"6940","key":"2062_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/bmj.308.6940.1311","volume":"308","author":"JG Edwards","year":"1994","unstructured":"Edwards JG. Risperidone for schizophrenia. BMJ. 1994;308(6940):1311\u20132 https:\/\/doi.org\/10.1136\/bmj.308.6940.1311.","journal-title":"BMJ."},{"key":"2062_CR4","volume-title":"Model list of essential medicines, 21st list, 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Model list of essential medicines, 21st list, 2019. Geneva: World Health Organization; 2019. Licence: CCBY-NC-SA3.0IGO. Last acessed: 20th April 2020. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325771\/WHO-MVP-EMP-IAU-2019.06-eng.pdf"},{"key":"2062_CR5","doi-asserted-by":"publisher","first-page":"i3846","DOI":"10.1136\/bmj.i3846","volume":"354","author":"O Dyer","year":"2016","unstructured":"Dyer O. Johnson & Johnson is ordered to pay $70m to boy who developed gynecomastia. Bmj. 2016;354:i3846 https:\/\/doi.org\/10.1136\/bmj.i3846 [published Online First: 2016\/07\/13].","journal-title":"Bmj"},{"key":"2062_CR6","unstructured":"drugwatch. Risperdal lawsuits, verdicts & settlements. Last accessed: 20th April 2020. Available: https:\/\/www.drugwatch.com\/risperdal\/lawsuits\/."},{"issue":"sep03 1","key":"2062_CR7","doi-asserted-by":"publisher","first-page":"e5916","DOI":"10.1136\/bmj.e5916","volume":"345","author":"JH Tanne","year":"2012","unstructured":"Tanne JH. Johnson & Johnson pays $181m for misleading marketing of risperidone. BMJ. 2012;345(sep03 1):e5916 https:\/\/doi.org\/10.1136\/bmj.e5916.","journal-title":"BMJ"},{"issue":"9","key":"2062_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1089\/cap.2015.0024","volume":"25","author":"M Etminan","year":"2015","unstructured":"Etminan M, Carleton B, Brophy JM. Risperidone and risk of gynecomastia in young men. J Child Adolesc Psychopharmacol. 2015;25(9):671\u20133 https:\/\/doi.org\/10.1089\/cap.2015.0024 [published Online First: 2015\/08\/20].","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9896","key":"2062_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London, England). 2013;382(9896):951\u201362 https:\/\/doi.org\/10.1016\/s0140-6736(13)60733-3 [published Online First: 2013\/07\/03].","journal-title":"Lancet (London, England)"},{"issue":"10202","key":"2062_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351 https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3.","journal-title":"Lancet"},{"issue":"2","key":"2062_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/01.jcp.0000203194.58087.9a","volume":"26","author":"L Holzer","year":"2006","unstructured":"Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol. 2006;26(2):167\u201371 https:\/\/doi.org\/10.1097\/01.jcp.0000203194.58087.9a.","journal-title":"J Clin Psychopharmacol"},{"issue":"9237","key":"2062_CR12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(00)02784-7","volume":"356","author":"GL Zornberg","year":"2000","unstructured":"Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000;356(9237):1219\u201323 https:\/\/doi.org\/10.1016\/S0140-6736(00)02784-7.","journal-title":"Lancet"},{"issue":"11","key":"2062_CR13","first-page":"1269","volume":"167","author":"E Wooltorton","year":"2002","unstructured":"Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167(11):1269\u201370.","journal-title":"CMAJ."},{"key":"2062_CR14","volume-title":"Comparative effectiveness review summary guides for clinicians","author":"Eisenberg Center at Oregon Health & Science University","year":"2007","unstructured":"Eisenberg Center at Oregon Health & Science University. Off-label use of atypical antipsychotic drugs: a summary for clinicians and policymakers. 2007 Jul 12. In:  Comparative effectiveness review summary guides for clinicians. Rockville: Agency for Healthcare Research and Quality (US); 2007. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK45281\/."},{"issue":"2","key":"2062_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40801-019-0151-7","volume":"6","author":"KA Oshikoya","year":"2019","unstructured":"Oshikoya KA, Carroll R, Aka I, Roden DM, van Driest SL. Adverse events associated with risperidone use in pediatric patients: a retrospective biobank study. Drugs Real World Outcomes. 2019;6(2):59\u201371 https:\/\/doi.org\/10.1007\/s40801-019-0151-7.","journal-title":"Drugs Real World Outcomes"},{"issue":"may12 7","key":"2062_CR16","doi-asserted-by":"publisher","first-page":"h2435","DOI":"10.1136\/bmj.h2435","volume":"350","author":"PC G\u00f8tzsche","year":"2015","unstructured":"G\u00f8tzsche PC, Young AH, Crace J. Does long term use of psychiatric drugs cause more harm than good? BMJ. 2015;350(may12 7):h2435 https:\/\/doi.org\/10.1136\/bmj.h2435.","journal-title":"BMJ"},{"issue":"1","key":"2062_CR17","doi-asserted-by":"publisher","first-page":"180268","DOI":"10.1038\/sdata.2018.268","volume":"5","author":"JS Ross","year":"2018","unstructured":"Ross JS, Waldstreicher J, Bamford S, Berlin JA, Childers K, Desai NR, et al. Overview and experience of the YODA project with clinical trial data sharing after 5 years. Sci Data. 2018;5(1):180268 https:\/\/doi.org\/10.1038\/sdata.2018.268.","journal-title":"Sci Data"},{"issue":"12","key":"2062_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.7326\/0003-4819-158-12-201306180-00009","volume":"158","author":"HM Krumholz","year":"2013","unstructured":"Krumholz HM, Ross JS, Gross CP, Emanuel EJ, Hodshon B, Ritchie JD, et al. A historic moment for open science: the Yale University open data access project and medtronic. Ann Intern Med. 2013;158(12):910\u20131 https:\/\/doi.org\/10.7326\/0003-4819-158-12-201306180-00009.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2062_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMp1607342","volume":"375","author":"HM Krumholz","year":"2016","unstructured":"Krumholz HM, Waldstreicher J. The Yale Open Data Access (YODA) project--a mechanism for data sharing. N Engl J Med. 2016;375(5):403\u20135 https:\/\/doi.org\/10.1056\/NEJMp1607342 [published Online First: 2016\/08\/16].","journal-title":"N Engl J Med"},{"key":"2062_CR20","unstructured":"Alexander Hodkinson. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder - a meta-analysis involving clinical study reports and individual patient data. PROSPERO 2019 CRD42019140556. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42019140556."},{"issue":"16","key":"2062_CR21","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657\u201365 https:\/\/doi.org\/10.1001\/jama.2015.3656.","journal-title":"JAMA."},{"issue":"oct14 2","key":"2062_CR22","doi-asserted-by":"publisher","first-page":"f5992","DOI":"10.1136\/bmj.f5992","volume":"347","author":"EH Turner","year":"2013","unstructured":"Turner EH. How to access and process FDA drug approval packages for use in research. BMJ. 2013;347(oct14 2):f5992 https:\/\/doi.org\/10.1136\/bmj.f5992.","journal-title":"BMJ"},{"key":"2062_CR23","unstructured":"European Medicines Agency. European public assessment reports. Last accessed on 22nd July 2020. Available at: https:\/\/www.ema.europa.eu\/en\/glossary\/european-public-assessment-report."},{"issue":"9","key":"2062_CR24","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","volume":"32","author":"S Leucht","year":"2007","unstructured":"Leucht S, Davis JM, Engel RR, et al. Defining \u2018response\u2019 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007;32(9):1903\u201310 https:\/\/doi.org\/10.1038\/sj.npp.1301325 [published Online First: 2007\/02\/09].","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"2062_CR25","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","volume":"31","author":"S Leucht","year":"2006","unstructured":"Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31(10):2318\u201325 https:\/\/doi.org\/10.1038\/sj.npp.1301147.","journal-title":"Neuropsychopharmacology."},{"issue":"8","key":"2062_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2215-0366(18)30177-9","volume":"5","author":"J Schneider-Thoma","year":"2018","unstructured":"Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry. 2018;5(8):653\u201363 https:\/\/doi.org\/10.1016\/s2215-0366(18)30177-9 [published Online First: 2018\/07\/26].","journal-title":"Lancet Psychiatry"},{"key":"2062_CR27","doi-asserted-by":"publisher","unstructured":"Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S, et al. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016;12 https:\/\/doi.org\/10.1002\/14651858.CD006918.pub3.","DOI":"10.1002\/14651858.CD006918.pub3"},{"key":"2062_CR28","doi-asserted-by":"publisher","unstructured":"Nussbaum AM, Stroup TS. Oral paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008;(2) https:\/\/doi.org\/10.1002\/14651858.CD006369.pub2.","DOI":"10.1002\/14651858.CD006369.pub2"},{"key":"2062_CR29","unstructured":"FDA prescribing information of RISPERDAL. Last accessed 21st July 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020588s046lbl.pdf."},{"key":"2062_CR30","unstructured":"The YODA Project. Research proposal 2019\u20133978. Available at: https:\/\/yoda.yale.edu\/data-request\/2019-3978."},{"key":"2062_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-244X-6-45","volume":"6","author":"GM Gharabawi","year":"2006","unstructured":"Gharabawi GM, Greenspan A, Rupnow MF, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry. 2006;6:45 https:\/\/doi.org\/10.1186\/1471-244x-6-45. [published Online First: 2006\/10\/24].","journal-title":"BMC Psychiatry"},{"key":"2062_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12888-014-0351-3","volume":"14","author":"AM Downing","year":"2014","unstructured":"Downing AM, Kinon BJ, Millen BA, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014;14:351 https:\/\/doi.org\/10.1186\/s12888-014-0351-3. [published Online First: 2014\/12\/30].","journal-title":"BMC Psychiatry"},{"issue":"2\u20133","key":"2062_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","volume":"152","author":"S Durgam","year":"2014","unstructured":"Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2\u20133):450\u20137 https:\/\/doi.org\/10.1016\/j.schres.2013.11.041. [published Online First: 2014\/01\/15].","journal-title":"Schizophr Res"},{"issue":"5","key":"2062_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa053222","volume":"354","author":"WG Honer","year":"2006","unstructured":"Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354(5):472\u201382 https:\/\/doi.org\/10.1056\/NEJMoa053222. [published Online First: 2006\/02\/03].","journal-title":"N Engl J Med"},{"issue":"8","key":"2062_CR35","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of Paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830\u20139 https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0241. [published Online First: 2015\/03\/31].","journal-title":"JAMA Psychiatry"},{"issue":"1\u20133","key":"2062_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1\u20133):117\u201330 https:\/\/doi.org\/10.1016\/j.schres.2007.03.003. [published Online First: 2007\/05\/01].","journal-title":"Schizophr Res"},{"key":"2062_CR37","unstructured":"European Medicines Agency Clinical Data. Online access to clinical data for medicinal products for human use. Last accessed 20th April 2020. Available at: https:\/\/clinicaldata.ema.europa.eu\/web\/cdp\/home."},{"key":"2062_CR38","unstructured":"InfoCuria Case-law. Opinion of advocate General Hogan delivered on 11th September 2019. Case C-175\/18 P. PTC Therapeutics International Ltd v European Medicines Agency (EMA). Last accessed on 22nd July 2020. Available at: http:\/\/curia.europa.eu\/juris\/document\/document.jsf?docid=217636&doclang=EN."},{"key":"2062_CR39","unstructured":"European Medicines Agency Science Medicines Health. EMA Management Board: highlights of October 2019 meeting. News 04\/10\/2019. Last accessed on 22nd July 2020. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-management-board-highlights-october-2019-meeting."},{"issue":"oct18 2","key":"2062_CR40","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928 https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"7382","key":"2062_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219 https:\/\/doi.org\/10.1136\/bmj.326.7382.219.","journal-title":"BMJ."},{"issue":"27","key":"2062_CR42","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1002\/sim.7431","volume":"36","author":"M Petropoulou","year":"2017","unstructured":"Petropoulou M, Mavridis D. A comparison of 20 heterogeneity variance estimators in statistical synthesis of results from studies: a simulation study. Stat Med. 2017;36(27):4266\u201380 https:\/\/doi.org\/10.1002\/sim.7431.","journal-title":"Stat Med"},{"key":"2062_CR43","volume-title":"Distribution theory for Glass\u2019s estimator of effect size and related estimators","author":"L Hedges","year":"1981","unstructured":"Hedges L. Distribution theory for Glass\u2019s estimator of effect size and related estimators; 1981."},{"issue":"9","key":"2062_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jpepsy\/jsp004","volume":"34","author":"JA Durlak","year":"2009","unstructured":"Durlak JA. How to select, calculate, and interpret effect sizes. J Pediatr Psychol. 2009;34(9):917\u201328 https:\/\/doi.org\/10.1093\/jpepsy\/jsp004.","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"2062_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25 https:\/\/doi.org\/10.1186\/1471-2288-14-25.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2062_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53\u201377 https:\/\/doi.org\/10.1002\/sim.2528. [published Online First: 2006\/04\/06].","journal-title":"Stat Med"},{"issue":"4","key":"2062_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14737167.2.4.367","volume":"2","author":"AJ Sutton","year":"2002","unstructured":"Sutton AJ, Cooper NJ, Lambert PC, et al. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res. 2002;2(4):367\u201379 https:\/\/doi.org\/10.1586\/14737167.2.4.367. [published Online First: 2002\/08\/01].","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"2062_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/biostatistics\/kxn034","volume":"10","author":"L Tian","year":"2009","unstructured":"Tian L, Cai T, Pfeffer MA, et al. Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. Biostatistics. 2009;10(2):275\u201381 https:\/\/doi.org\/10.1093\/biostatistics\/kxn034. [published Online First: 2008\/10\/14].","journal-title":"Biostatistics"},{"issue":"8","key":"2062_CR49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jclinepi.2012.12.017","volume":"66","author":"G Abo-Zaid","year":"2013","unstructured":"Abo-Zaid G, Guo B, Deeks JJ, et al. Individual participant data meta-analyses should not ignore clustering. J Clin Epidemiol. 2013;66(8):865\u201373.e4 https:\/\/doi.org\/10.1016\/j.jclinepi.2012.12.017. [published Online First: 2013\/05\/04].","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2062_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jrsm.1303","volume":"9","author":"E Kontopantelis","year":"2018","unstructured":"Kontopantelis E. A comparison of one-stage vs two-stage individual patient data meta-analysis methods: a simulation study. Res Synth Methods. 2018;9(3):417\u201330 https:\/\/doi.org\/10.1002\/jrsm.1303.","journal-title":"Res Synth Methods"},{"issue":"3","key":"2062_CR51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/schbul\/sbp124","volume":"36","author":"M Obermeier","year":"2010","unstructured":"Obermeier M, Mayr A, Schennach-Wolff R, et al. Should the PANSS be rescaled? Schizophr Bull. 2010;36(3):455\u201360 https:\/\/doi.org\/10.1093\/schbul\/sbp124. [published Online First: 2009\/11\/04].","journal-title":"Schizophr Bull"},{"key":"2062_CR52","doi-asserted-by":"publisher","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. 2011;45(3):67. https:\/\/doi.org\/10.18637\/jss.v045.i03. [published Online First: 2011-12-12].","DOI":"10.18637\/jss.v045.i03"},{"issue":"5","key":"2062_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/sim.7141","volume":"36","author":"DL Burke","year":"2017","unstructured":"Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36(5):855\u201375 https:\/\/doi.org\/10.1002\/sim.7141.","journal-title":"Stat Med"},{"issue":"7745","key":"2062_CR54","first-page":"521","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ Br Med J. 2010;340(7745):521\u20135.","journal-title":"BMJ Br Med J"},{"key":"2062_CR55","volume-title":"Stata statistical software: release 16","author":"StataCorp","year":"2019","unstructured":"StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC [program]; 2019."},{"issue":"3","key":"2062_CR56","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/1536867X1301300308","volume":"13","author":"E Kontopantelis","year":"2013","unstructured":"Kontopantelis E, Reeves D. A short guide and a forest plot command (Ipdforest) for one-stage meta-analysis. Stata J. 2013;13(3):574\u201387 https:\/\/doi.org\/10.1177\/1536867x1301300308.","journal-title":"Stata J"},{"issue":"5","key":"2062_CR57","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/sim.7171","volume":"36","author":"H Hua","year":"2017","unstructured":"Hua H, Burke DL, Crowther MJ, Ensor J, Tudur Smith C, Riley RD. One-stage individual participant data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across-trial information. Stat Med. 2017;36(5):772\u201389 https:\/\/doi.org\/10.1002\/sim.7171.","journal-title":"Stat Med"},{"issue":"15","key":"2062_CR58","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1002\/sim.2768","volume":"26","author":"MC Simmonds","year":"2007","unstructured":"Simmonds MC, Higgins JPT. Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Stat Med. 2007;26(15):2982\u201399 https:\/\/doi.org\/10.1002\/sim.2768.","journal-title":"Stat Med"},{"issue":"11","key":"2062_CR59","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358 https:\/\/doi.org\/10.1002\/sim.1186 [published Online First: 2002\/07\/12].","journal-title":"Stat Med"},{"issue":"7414","key":"2062_CR60","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360 https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"2062_CR61","unstructured":"FDA prescribing information for INVEGA (paliperidone). Last accessed 21st July 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021999s018lbl.pdf."},{"key":"2062_CR62","unstructured":"FDA prescribing information for INVEGA SUSTENNA (Paliperidone palmitate). Last accessed on 21st July 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022264s023lbl.pdf."},{"key":"2062_CR63","unstructured":"Summary of Product Characteristics (SmPCs) of INVEGA. Last accessed on 21st July 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/invega-epar-product-information_en.pdf."},{"key":"2062_CR64","unstructured":"Summary of Product Characteristics (SmPCs) of TREVICTA. Last accessed on 21st July 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trevicta-epar-product-information_en.pdf."},{"key":"2062_CR65","doi-asserted-by":"publisher","unstructured":"Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012;(6) https:\/\/doi.org\/10.1002\/14651858.CD008296.pub2.","DOI":"10.1002\/14651858.CD008296.pub2"},{"issue":"7","key":"2062_CR66","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","volume":"11","author":"M Haas","year":"2009","unstructured":"Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11(7):687\u2013700 https:\/\/doi.org\/10.1111\/j.1399-5618.2009.00750.x. [published Online First: 2009\/10\/21].","journal-title":"Bipolar Disord"},{"issue":"6","key":"2062_CR67","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/cap.2008.0144","volume":"19","author":"M Haas","year":"2009","unstructured":"Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611\u201321 https:\/\/doi.org\/10.1089\/cap.2008.0144. [published Online First: 2009\/12\/29].","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"2062_CR68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","volume":"27","author":"M Kramer","year":"2007","unstructured":"Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27(1):6\u201314 https:\/\/doi.org\/10.1097\/JCP.0b013e31802dda4a. [published Online First: 2007\/01\/17].","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2062_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","volume":"16","author":"A Tzimos","year":"2008","unstructured":"Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008;16(1):31\u201343 https:\/\/doi.org\/10.1097\/JGP.0b013e31815a3e7a. [published Online First: 2008\/01\/01].","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"2062_CR70","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","volume":"166","author":"CM Canuso","year":"2009","unstructured":"Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009;166(6):691\u2013701 https:\/\/doi.org\/10.1176\/appi.ajp.2009.08040613. [published Online First: 2009\/05\/05].","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2062_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247\u201356 https:\/\/doi.org\/10.1097\/YIC.0b013e32833948fa. [published Online First: 2010\/04\/15].","journal-title":"Int Clin Psychopharmacol"},{"key":"2062_CR72","unstructured":"Akihide W, Nagahide T, Masayoshi T et al.. Evaluation of efficacy and safety of paliperidone palmitate with schizophrenia: subpopulation analysis of Japanese patients in the 13-week, double-blind, randomized, placebo-controlled Asian study. J-GLOBAL ID: 201302271227372158. Available at: https:\/\/jglobal.jst.go.jp\/en\/detail?JGLOBAL_ID=201302271227372158&rel=0."},{"key":"2062_CR73","unstructured":"RIS-USA-72. The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia. Last accessed: 12th July 2021. Available at: https:\/\/yoda.yale.edu\/safety-and-efficacy-risperidone-8-mg-qd-and-4-mg-qd-compared-placebo-treatment-schizophrenia."},{"issue":"1\u20133","key":"2062_CR74","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jad.2010.09.011","volume":"129","author":"J Berwaerts","year":"2011","unstructured":"Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord. 2011;129(1\u20133):252\u201360.","journal-title":"J Affect Disord"},{"issue":"3","key":"2062_CR75","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jad.2012.01.047","volume":"138","author":"J Berwaerts","year":"2012","unstructured":"Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord. 2012;138(3):247\u201358.","journal-title":"J Affect Disord"},{"issue":"5","key":"2062_CR76","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","volume":"71","author":"CM Canuso","year":"2010","unstructured":"Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010;71(5):587\u201398.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2062_CR77","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/JCP.0b013e3181eeb600","volume":"30","author":"CM Canuso","year":"2010","unstructured":"Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and\/or mood stabilizers. J Clin Psychopharmacol. 2010;30(5):487\u201395.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"2062_CR78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4088\/JCP.14m09416","volume":"76","author":"DJ Fu","year":"2015","unstructured":"Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76(3):253\u201362.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2062_CR79","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","volume":"161","author":"RM Hirschfeld","year":"2004","unstructured":"Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161(6):1057\u201365.","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"2062_CR80","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","volume":"116","author":"D Hough","year":"2010","unstructured":"Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2\u20133):107\u201317.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"2062_CR81","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1\u20133):147\u201361.","journal-title":"Schizophr Res"},{"issue":"6","key":"2062_CR82","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125\u201332.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2062_CR83","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1461145709990988","volume":"13","author":"M Kramer","year":"2010","unstructured":"Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635\u201347.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"2062_CR84","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1017\/S1092852900000456","volume":"15","author":"M Kramer","year":"2010","unstructured":"Kramer M, Simpson G, Maciulis V, Kushner S, Liu Y, Lim P, et al. One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia. CNS Spectr. 2010;15(8):506\u201314.","journal-title":"CNS Spectr"},{"issue":"5","key":"2062_CR85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/YIC.0b013e3281c55f4f","volume":"22","author":"R Luthringer","year":"2007","unstructured":"Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol. 2007;22(5):299\u2013308.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"2062_CR86","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1399-5618.2009.00761.x","volume":"11","author":"W Macfadden","year":"2009","unstructured":"Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827\u201339.","journal-title":"Bipolar Disord"},{"issue":"12","key":"2062_CR87","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","volume":"62","author":"SR Marder","year":"2007","unstructured":"Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363\u201370.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"2062_CR88","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/npp.2010.79","volume":"35","author":"HA Nasrallah","year":"2010","unstructured":"Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072\u201382.","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"2062_CR89","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","volume":"30","author":"GJ Pandina","year":"2010","unstructured":"Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235\u201344.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2062_CR90","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","volume":"68","author":"JA Quiroz","year":"2010","unstructured":"Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156\u201362.","journal-title":"Biol Psychiatry"},{"key":"2062_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pnpbp.2014.02.007","volume":"53","author":"Q Rui","year":"2014","unstructured":"Rui Q, Wang Y, Liang S, Liu Y, Wu Y, Wu Q, et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;53:45\u201353.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"7","key":"2062_CR92","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","volume":"159","author":"GS Sachs","year":"2002","unstructured":"Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146\u201354.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"2062_CR93","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","volume":"70","author":"J Singh","year":"2011","unstructured":"Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011;70(12):1179\u201387.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"2062_CR94","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.euroneuro.2004.06.003","volume":"15","author":"AB Smulevich","year":"2005","unstructured":"Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15(1):75\u201384.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"2062_CR95","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.euroneuro.2012.03.004","volume":"22","author":"E Vieta","year":"2012","unstructured":"Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012;22(11):825\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"2062_CR96","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1399-5618.2010.00815.x","volume":"12","author":"E Vieta","year":"2010","unstructured":"Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010;12(3):230\u201343.","journal-title":"Bipolar Disord"},{"issue":"9","key":"2062_CR97","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40263-017-0437-9","volume":"31","author":"S Gopal","year":"2017","unstructured":"Gopal S, Lane R, Nuamah I, et al. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with Paliperidone extended-release (ER) for 2 years: a post hoc analysis of an open-label multicenter study. CNS Drugs. 2017;31(9):797\u2013808 https:\/\/doi.org\/10.1007\/s40263-017-0437-9. [published Online First: 2017\/07\/01].","journal-title":"CNS Drugs"},{"key":"2062_CR98","unstructured":"the YODA PROJECT. The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia. Last accessed on 22nd July 2020. Available at: https:\/\/yoda.yale.edu\/safety-and-efficacy-risperidone-8-mg-qd-and-4-mg-qd-compared-placebo-treatment-schizophrenia."},{"key":"2062_CR99","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1192\/bjp.176.3.249","volume":"176","author":"M Marshall","year":"2000","unstructured":"Marshall M, Lockwood A, Bradley C, et al. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000;176:249\u201352 https:\/\/doi.org\/10.1192\/bjp.176.3.249. [published Online First: 2001\/02\/07].","journal-title":"Br J Psychiatry"},{"issue":"1","key":"2062_CR100","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13063-016-1327-z","volume":"17","author":"A Hodkinson","year":"2016","unstructured":"Hodkinson A, Gamble C, Smith CT. Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials. Trials. 2016;17(1):207 https:\/\/doi.org\/10.1186\/s13063-016-1327-z.","journal-title":"Trials."},{"key":"2062_CR101","doi-asserted-by":"publisher","first-page":"f3981","DOI":"10.1136\/bmj.f3981","volume":"346","author":"MA Rodgers","year":"2013","unstructured":"Rodgers MA, Brown JVE, Heirs MK, Higgins JPT, Mannion RJ, Simmonds MC, et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ. 2013;346:f3981 https:\/\/doi.org\/10.1136\/bmj.f3981.","journal-title":"BMJ."},{"key":"2062_CR102","unstructured":"Clinical Study Data Request. Last accessed: 30 April 2020. Available at: https:\/\/www.clinicalstudydatarequest.com\/."},{"issue":"1","key":"2062_CR103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13643-018-0766-x","volume":"7","author":"A Hodkinson","year":"2018","unstructured":"Hodkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, Doshi P, et al. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. Syst Rev. 2018;7(1):117 https:\/\/doi.org\/10.1186\/s13643-018-0766-x.","journal-title":"Syst Rev"},{"issue":"6","key":"2062_CR104","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bmjebm-2018-110963","volume":"23","author":"T Jefferson","year":"2018","unstructured":"Jefferson T, Doshi P, Boutron I, et al. When to include clinical study reports and regulatory documents in systematic reviews. BMJ Evid Based Med. 2018;23(6):210\u20137 https:\/\/doi.org\/10.1136\/bmjebm-2018-110963. [published Online First: 2018\/10\/13].","journal-title":"BMJ Evid Based Med"},{"issue":"1","key":"2062_CR105","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12874-019-0836-3","volume":"19","author":"J-M Ferran","year":"2019","unstructured":"Ferran J-M, Nevitt SJ. European medicines agency policy 0070: an exploratory review of data utility in clinical study reports for academic research. BMC Med Res Methodol. 2019;19(1):204 https:\/\/doi.org\/10.1186\/s12874-019-0836-3.","journal-title":"BMC Med Res Methodol"},{"key":"2062_CR106","unstructured":"Health Canada. Draft guidance document. Public Release of Clinical Information. Last accessed: 30th April 2020. Available at: https:\/\/www.canada.ca\/en\/health-canada\/programs\/consultation-public-release-clinical-information-drug-submissions-medical-device-applications\/draft-guidance.html."},{"key":"2062_CR107","unstructured":"FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs. FDA news release January 16, 2018. Last accessed 28th August. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-commissioner-scott-gottlieb-md-new-steps-fda-taking-enhance-transparency-clinical-trial."},{"key":"2062_CR108","unstructured":"World Health Organization. International Clinical Trials Registry Platform (ICTRP). Joint statement on public disclosure of results from clinical trials on 18 May 2017. Last accessed 28th August 2020. Available at: https:\/\/www.who.int\/ictrp\/results\/jointstatement\/en\/."},{"issue":"jun04 2","key":"2062_CR109","doi-asserted-by":"publisher","first-page":"g3510","DOI":"10.1136\/bmj.g3510","volume":"348","author":"E Maund","year":"2014","unstructured":"Maund E, Tendal B, Hr\u00f3bjartsson A, et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ. 2014;348(jun04 2):g3510 https:\/\/doi.org\/10.1136\/bmj.g3510.","journal-title":"BMJ"},{"issue":"oct12 1","key":"2062_CR110","doi-asserted-by":"publisher","first-page":"c4737","DOI":"10.1136\/bmj.c4737","volume":"341","author":"D Eyding","year":"2010","unstructured":"Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010;341(oct12 1):c4737 https:\/\/doi.org\/10.1136\/bmj.c4737.","journal-title":"BMJ"},{"key":"2062_CR111","doi-asserted-by":"publisher","first-page":"d8141","DOI":"10.1136\/bmj.d8141","volume":"344","author":"B Wieseler","year":"2012","unstructured":"Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ. 2012;344:d8141 https:\/\/doi.org\/10.1136\/bmj.d8141.","journal-title":"BMJ."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02062-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02062-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02062-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T21:02:54Z","timestamp":1629838974000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02062-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02062-w","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/O1YL2W","asserted-by":"object"},{"id-type":"doi","id":"10.32388\/VPQK8N","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}